Business Wire

Scientist.com Hosts Human Biospecimen Webinar Featuring International Panel of Industry Thought Leaders

Share

Scientist.com, the life science industry’s leading online marketplace for outsourced research services, announced today that it has assembled a panel of global experts on the use of human biospecimens in drug research. Set for May 14, 2018, at 9:30am EDT, the webinar will cover a variety of topics, including the sustainability of biobanks, the regulations surrounding human biospecimens and the potential benefits of pre-competitive collaboration.

“We are excited to have assembled such a distinguished panel on one of the most important topics within the life science community today—the use of human biospecimens in drug discovery,” said Matt McLoughlin, Sr. Director of Compliance at Scientist.com. “Human biospecimens are increasingly being used in all aspects of pre-clinical and clinical research. This is a fantastic opportunity for different stakeholders to share perspectives that will benefit the entire research community.”

The panel consists of experts in biobanking, international governance, compliance assessment and sample acquisition, including Dr. Sam Jackson of the UK-based National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3R); Erik Steinfelder, Director General of the Biobanking and Biomolecular Resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC); Matt McLoughlin, Scientist.com’s Senior Director of Compliance; and Dr. Sonja Grosskinsky of Lonza, a Switzerland-based life science solutions provider.

Go here to register for the free webinar, “Human Biological Samples: Promoting Collaboration Within the Research Community to Advance Drug Discovery.”

About Scientist.com

Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

Contact information

Media:
Scientist.com
Sean Preci
Director of Communications
+1 858 455-1300 ext. 401
marketing@scientist.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Defence Unlimited International Corp. is Hiring Veterans17.7.2019 20:58:00 CESTPress release

Defence Unlimited International is one of the fastest growing companies operating within the defence and security space. Defence Unlimited International has adopted a unique outsourced model which integrates multiple partners both individual and corporate, on its projects. This has enabled it to offer and deliver to its clients best of breed bespoke solutions. Whilst Defence Unlimited is pursuing its drive towards achieving a more global footprint in its operations, the founder, Edward Banayoti firmly reiterates the continued commitment of the company to its existing strategy of identifying and successfully deploying experienced individuals that have served in the military. Individuals and teams with such experience can offer invaluable value added within projects Defence Unlimited are active in or are in the process of executing. "We take pride in our track record of offering numerous opportunities to Veterans who have served their country, giving such individuals who have heeded a pa

Gartner Names Airship a Leader, Positioned Highest in Execution and Furthest in Vision in the Magic Quadrant for Mobile Marketing Platforms17.7.2019 15:59:00 CESTPress release

Customer engagement company Airship today announced that it has been named a Leader by Gartner, Inc. in its 2019 Magic Quadrant for Mobile Marketing Platforms1. Among 18 vendors evaluated, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision. A complimentary copy of the full report is available from Airship. “We believe Gartner’s positioning of Airship validates our unique ability to deliver innovative, transformative digital customer experiences for the world’s leading brands,” said Brett Caine, CEO and president, Airship. “Airship delivers rich messages with pinpoint accuracy on whatever channel is most convenient and effective for the customer. Today’s customer expects proactive information and real-time response, and Airship is the essential component that makes it all possible.” According to Gartner, “Globally, consumers spend more of their time on smartphones than on desktops, laptops or tablets. This broad and rapid consumer a

GSMA Signs £38 Million Funding Partnership With the Department of International Development17.7.2019 15:02:00 CESTPress release

The GSMA today announced that it has signed a thirty-eight million-pound partnership with the UK’s Department for International Development (DFID). The ‘Partnership for Inclusion, Innovation and Scale’ will provide funding for the GSMA’s Mobile for Development work on digital inclusion, digital identity, energy, water, sanitation and the reduction of the mobile gender gap. It will also include two new areas of focus: disability and climate. “This landmark partnership with DFID reinforces the joint power and potential of the private and public sectors working together and ensures that we will continue our crucial role of stimulating digital innovation to deliver both sustainable business and large-scale socio-economic impact for the underserved,” said Mats Granryd, Director General, GSMA. “This project reinforces our commitment to supporting the UN’s Sustainable Development Goals and using the power of technology to reduce global inequalities.” Inclusion, Innovation and Scale The partne

Gilead Sciences Announces Changes to Senior Leadership Team17.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function. Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization. “Gregg has been a valued leader at Gilead for nearly 20

Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company17.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation. “Over the past nine years, John’s scientific contributions and le